The Korean Journal of Nuclear Medicine (대한핵의학회지)

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Synthesis of Substrates for Gene Therapy Monitoring of HSV1-TK System

유전자 영상용 HSV1-TK 기질의 합성

  • Choi, Tae-Hyun (Laboratory of Cyclotron Applicationl, Korea Cancer Center Hospital) ;
  • Ahn, Soon-Hyuk (Laboratory of Cyclotron Applicationl, Korea Cancer Center Hospital) ;
  • Choi, Chang-Woon (Laboratory of Cyclotron Applicationl, Korea Cancer Center Hospital) ;
  • Lim, Sang-Moo (Laboratory of Cyclotron Applicationl, Korea Cancer Center Hospital) ;
  • Awh, Ok-Doo (College of Health Science, Yonsei University)
  • 최태현 (원자력병원 싸이클로트론 응용연구실) ;
  • 안순혁 (원자력병원 싸이클로트론 응용연구실) ;
  • 최창운 (원자력병원 싸이클로트론 응용연구실) ;
  • 임상무 (원자력병원 싸이클로트론 응용연구실) ;
  • 오옥두 (연세대학교 임상병리학과)
  • Published : 2002.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : In gene therapy, tumor cells expressing the herpes simplex virus thymidine kinase are sensitive to prodrugs. Potential prodrugs IVDU and IVFRU were synthesized and radiolabeled with radioiodine for noninvasive imaging of herpes simplex virus type 1 gene expression. Material and Methods : 5-(2-trimethysilyl) vinyl-2'-deoxyuridine and 5-(2-trimethylsilyl)vinyl-2'-fluoro-2'-deoxyuridine, precursors of 5-(2--iodo)viny l-2'-deoxy uridine(IVDU) and 5-(2-iodo)-2'-vinyl-2'-deoxy-2'-fluororibofuranosyl uracil(IVFRU), were synthesized from reaction of trans-1-trimethylsillyl-2-tri-n-butylstannylethylene with 5-iodo-2'-deoxyuridine and 5-iodo-2'-fluoro-2'-deoxyuridine, respectively, on the condition of Pd catalyst. These precursors were separated from reaction mixture by silica gel column chromatography method. Each precursor was radioiodinated with radioiodine by mixing with ICI oxidizing agent. These radioiodinated compounds were purified with HPLC. Radiohalogen exchange has been shown to be effective for the synthesis of products with lower specific activity. Similarly, carrier-added and high specific activity products have been isolated in respectable radiochemical yields using ICI method. Results : Synthetic yield of precursors, IVDU and IVFRU were 43% and 18%, respectively. Radiochemical purity of both compunds was over 98%. Conclusion : We synthesized precursors of IVDU and IVFRU for monitoring of HSV1-tk gene expression. Radiotracers were radioiodinated with high radiolabeling yield by ICI method.

목적: 유전자 치료에서, 종양세포에 herpes simplex virus thymidine kinase 유전자를 발현시키고 이에 민감한 prodrug을 전신투여하여 발현된 종양세포에 특이적으로 집적되는 방법은 매우 효율적인 방법이다. 대표적인 prodrug인, IVDU, IVFRU는 herpes simplex virus type 1의 비침습적 영상화 방법에 응용되는 방사옥소 표지가능 화합물이다. 재료 및 방법: Trans-l-trimethylsilyl-2-tri-n-butylstannylethylene과 uridine 변형체상의 iodo-uracil을 Pd촉매하에서 반응시켜 표지전구체인 5-trimethylvinyl-deoxy-uridine과 5-trimethylsilylvinyl-deoxy-fluororibofuranosyl uracil을 합성하였다. 이것을 column chromatography의 방법으로 분리 정제하였다. 합성한 각 전구체를 ICI 담체를 이용하여 높은 수율로 표지하였고, HPLC를 사용하여 분리하였다. Radiohalogen exchange 방법은 비방사능을 낮게 할수록 표지에 효율적으로 알려져 있다. 이 방법으로 ICI 방법을 사용하여 담체를 포함하는 높은 방사능의 화합물을 얻을 수 있다. 결과: IVDU와 IVFRU 표지를 위한 전구체 합성수율은 각각 43, 72% 였다. ICl로 담체를 이용한 표지방법을 사용하여 IVDU와 IVFRU 표지수율은 98% 이상이었다. 결론: HSV1-tk를 이용한 유전자 영상용 기질의 전구체를 성공적으로 합성하였고. 95% 이상의 높은 표지수율의 유전자 영상용 방사성 추적자를 성공적으로 제조하였다.

Keywords

References

  1. Ichiro K, Yoshihiro S, Akihiro M, Fumitaka S,Yuji M. cAMP stimulates the bystander effct insuicide gene therapy of human choriocarcinoma.Anticancer Res 1998;18:3411-20.
  2. Svend F, Kenneth R, Dell P, Jeff G, Kim J. Anovel three-pronged approach to kill cancer cellsselectivity: concomitant viral, double suicidegene, and radiotherapy. Human gene therapy1998;9:1323-33.
  3. Toda M, Martuza L, Rabkin D. Combinationsuicede{cytokine gene therapy as adjuvants to adefective herpes simplex virus-based cancer. GeneTherapy 2001;8:332-9.
  4. Kokoris S, Sabo P, Black E. In vitro evaluation ofmutant HSV1 thymidine kinases for suicide genetherapy. Anticancer Res 2000;20:959-63.
  5. Ramesh R, Munshi A, Marrogi J, Freeman M.Enhancement of tumor killing using acombination of tumor immunization and HSV-tksuicide gene therapy. Int J Cancer 1999;80:380-6.
  6. Thust R, Tomicic M, Klocking R, Wutzler P,Kaina B. Cytogenetic genotoxicity of anti-herpespurine nucleoside analogues in CHO cellsexpressing the thymidine kinase gene of herpessimplex virus type1: comparison of ganciclovir,penciclovir and aciclovir. Mutagenesis 2000;15:177-84.
  7. Beltinger C, Fulda S, Kammertoens T, Uckert W,Debatin M. Mitochondrial amplification of deathsignals determines thymidine kinase{ganciclovirtriggeredactivation of apoptosis. Cancer Research2000;60:3212-17.
  8. Ilonka G, Leo W, Ronald F, Jacek K, Regin W.Radiosynthesis and quality assurance of 5-[1241]Iodo-2' -deoxyuridine for functional PET imagingof cell proliferation. Nucl Med BioI 1998 ; 25 :350-65.
  9. Juri T, Ronald P, Kyoichi W, Revathi J,Takamitsu 0, John K, et al. Noninvasiveimaging of herpes simplex virus thymidinekinase gene transfer and expression: a potentialmethod. Cancer Res 1996;56:4087-95.
  10. Juri T, Gunher S, Revanti D, Hisao D, Kyoichi W, Bernd G, et al. Imaging the expression of transfected genes in vivo. Cancer Res 1995;55:6126-32.
  11. Kurt Z, Tandra C, Donald B, James M, Buck R.Simultaneous evaluation of dual gene transfer toadherent cells by gamma-ray imaging. Nucl MedBioi 2001;28:135-44.
  12. Tokumi M, Kunihiko D, Yoshiko S, Douglas R.Synthesis and anti-HIV activity of 6-substitutedpurine 2' -deoxy-2' -fluororibosides. Nucleosides& Nucleotides 1994;13:527-37
  13. Tokumi M, Kunihiko D, Yoshiko S, Douglas R.Synthesis and anti-HIV activity of 6-substitutedpurine 2' -deoxy-2' -fluororibosides. Nucleosides& Nucleotides 1994;13:527-37.
  14. Erik C, Claude D, Piet H, lain S, Stanley J,Michael. Synthesis and anti viral activity of(E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine. J Med Chem 1986;29:213-17.
  15. Erik C. Biochemical aspects of the selectiveantiherpes activity of nucleoside analogues.Biochem Pharmacol 1984;33:2159-69.
  16. Hayes D, John H, Jeffrey W, Donald L.Synthesis and radioiodination of a stannyloligodeoxyribonucleotide. Nucl Aicds Res 1997;25:2897-901.
  17. Robert M, Anna S, Johanna B; B1anka R, MariaK, Manfred M, et al. Transcription and activityof 5-fluorouracil converting enzymes influoropyrimidine resistance in colon cancer invitro. Biochem Pharmacol 1997;54:1233-42.
  18. James S, Kassis A, Amin K. Instantaneouspreparation of radiolabeled 5-iodo-2'-deoxyuridine.Appl Radiat Isot 1994;46:1039-46.
  19. Knaus E, Leonard W, Tyrrell D. Synthesis of1311, 1251 and 82Br labelled (E)-5-(2-halovinyl)2'-deoxyuridines. Int J Apl Radiat Isot 1984;35:1049-52.
  20. Moris R, Stefano M, Steven W, James W, BruceR, Stephan S. Nucleic acid related compunds.65 . New syntheses of 1-(fl -D-arabinofuranosyl)-5(E)- (2-iodovinyl)uracil(IVaraU) from vinylsilaneprecursors. Radioiodine uptake as a marker forthymidine kinase positive herpes viral infections.J Med Chern 1991;34:2275-80.
  21. Haberkorn U, Bellmann M, Gerlach L, Morr I,Trojan H, Brix G, et al. Uncoupling of 2-fluoro2-deoxyglucose transort and phosphorylationin rat hepatoma during gene therapy with HSVthymidine kinase. Gene Therapy 1998;5:880-87.
  22. Kevin M, Morin A, Edward K, Leonard W.Synthesis and cellular uptake of 2' -substitutedanalogues of (E)-5-(2-['25I]Iodovinyl)-2'-deoxyuridinein tumor cells transduced with the herpessimplex type-I. J Med Chem 1997;40:2184-92.
  23. John S, Gill G, Takashi I, Dorothy T, Tyrrell D,Edward K et al. Pharmacokinetics andmetabolism of E-5-(2-[l3lI]1odovinyl)-2'-deoxyuridinein dogs. Antimicrob Agents & chemother1986;29:320-4.
  24. Kelvin 0, Danny M, Suzanne B, Gholam H,Zbigniew D. The preparation of protectedarabinonuc1eosides. Can J Chern 1983;61: 120412.
  25. Kelvin 0, Gholam H, Zbigniew P, Danny M.Silylated derivatives of arabinonuc1eosides.Tetrahedron Letters 1982;23:1997-2000.
  26. Hayes D, Bruce R, Donal L, Stephan S.No-carrier-added ['231] 1-(f3 -D-arabinofuranosyl)5(E)-(2-iodovinyl)uracil(IVaraU): high yieldingradiolabeling via organotin and exchangereactions. Appl Radiat Isot 1994;45:795-801.
  27. Roland H, Chyng-Yann S, Abass A, Douglas M,Grace G, Hongming Z, et al. Kinase genetransfer to tumour-bearing rodents using positrionemission tomography and ['8F]FHPG. Eur JNucl Med 2001;28:5-12.
  28. Olafur G, Mats B, Stefan K, Feng W, Gunnar N,Karl-Johan F, et al. PET study does not supportits use as a proliferation marker. Nucl Med Bioi2001;28:59-65.